Tasrif Pharmaceutical
Discovering Novel Immunotherapeutics Against Cancer
Tasrif Pharmaceutical is a preclinical stage company and none of the products are FDA approved.
Who We Are
Founded in 2018, Tasrif Pharmaceutical’s focus is on novel immunotherapeutics targeting the poliovirus receptor (CD155).
Our Target: CD155
Tasrif Pharmaceutical has developed a panel of humanized monoclonal antibodies against CD155.
Platform Technology
Checkpoint Inhibitor, ADCs, Bispecifics, T-Cell Engager, CAR-T and CAR-NK Cells targeting CD155 for the treatment of cancer.
Tasrif Pharmaceutical 